Medical device giants Edwards Lifesciences Corp. and Boston Scientific Corp. have obtained new CE marks on their transcatheter aortic valve replacement (TAVR) products, the companies announced at the ongoing Paris Course of Revascularization (PCR) London Valves meeting in London.
Edwards’ Sapien 3 valve has been granted a CE mark to use the device in patients suffering from severe, symptomatic aortic stenosis who are at intermediate risk for open-heart surgery....